Bacteriological, pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field
Motohiro, T.; Handa, S.; Yamada, S.; Oki, S.; Yoshinaga, Y.; Oda, K.; Sakata, Y.; Kato, H.; Yamashita, F.; Imai, S.
Japanese Journal of Antibiotics 47(12): 1728-1752
1994
ISSN/ISBN: 0368-2781 PMID: 7877254 Document Number: 424793
Antibacterial activities were determined and pharmacokinetics and a clinical studies were performed on biapenem (L-627), a novel parenteral carbapenem antibiotic, in infections in children. The following results were obtained: 1. MICs of L-627 against clinical isolates were as follows: Among Gram-positive bacteria, MICs were 0.78 mu-g/ml to gt 100 mu-g/ml against 3 strains of methicillin-resistant Staphylococcus aureus (MRSA), and 0.10 mu-g/ml to 0.39 mu-g/ml against 8 strains of methicillin-sensitive S. aureus (MSSA), MICs against 5 of them were similar to those of imipenem (IPM), and MICs against 3 of them were slightly higher than those of IPM. MICs were ltoreq 0.025 mu-g/ml to 0.39 mu-g/ml against 7 strains of Streptococcus pneumoniae, and were similar to those of IPM, and lower than those of ceftazidime (CAZ) and piperacillin (PIPC). Among Gram-negative bacteria, MICs were 0.78 mu-g/ml and 3.13 mu-g/ml against 2 strains of Haemophilus influenzae, and were similar to those of IPM. 2. Maximum plasma concentrations determined by the bioassay method after intravenous infusion of L-627 over 30 minutes at doses of 6.0 and 12.0 mg/kg, respectively, in 2 different pairs of 2 children each (total 4 cases) were observed upon completion of the treatment. Maximum concentrations at a dose of 6.0 mg/kg were 28.8 mu-g/ml and 24.6 mu-g/ml, and at a dose of 12.0 mg/kg were 65.4 mu-g/ml and 39.6 mu-g/ml, exhibiting a dose response. Plasma half lives in the beta phase were 0.97 and 1.20 hours at 6.0 mg/kg, and 0.72 and 0.94 hour at 12.0 mg/kg. Plasma concentrations determined by the HPLC method were lower than those determined by the bioassay. 3. Urinary excretion rates in the first 5.5 hours after the 6.0 mg/kg dose were 81.4 and 75.3%, and after the 12.0 mg/kg dose were 91.0 and 73.8%, and these values were higher than those obtained using HPLC. 4. Concentrations of L-627 in cerebrospinal fluid were determined in 2 cases of purulent meningitis. In one case, 30.3 mg/kg of L-627 was infused intravenously over 30 minutes and concentrations on days 1, 3, 7 and 14 observed at 60, 60, 45 and 45 minutes after respective dosages were 7.60, 1.30, 1.42 and 0.38 mu-g/ml. Cerebrospinal fluid-plasma concentration ratio was determined on days 7 and 14 to be 5.5 and 1.2% respectively. In another case, in which 25.6 mg/kg of L-627 was infused intravenously over 30 minutes, concentrations on days 2, 3, 4, 5, and 9 observed at 60 minutes, and days 19 at 120 minutes after respective dosage were 1.08, 0.62, 0.54, 1.52, 1.50 and 0.80 mu-g/ml. Cerebrospinal fluid-plasma concentration ratios were determined on days 2, 4, 9 and 19, and the ratios were, respectively, 13.3, 4.5, 8.4 and 9.6%. 5. Clinical efficacies were evaluated in 50 cases (14 illness). Poor effects were obtained in 2 out of 20 cases with pneumonia, fair response in one case with acute sinusitis, and fair and poor responses in 2 cases out of 3 with subcutaneous abscess. All other cases showed excellent or good responses. Thus an efficacy rate of 90.0% was obtained. 6. Bacteriological efficacy was examined for 31 strains (9 species). 2 out of 12 strains of S. aureus remained unchanged, but in all the other 29 strains, bacteria were eradicated. Thus the eradication rate was 93.5%. 7. A side effect of diarrhea was observed in one patient (2.0%). 8. Abnormal laboratory test results included eosinophilia in 4 cases (9.5%), increased platelets in 3 cases (6.8%), simultaneous increases in GOT and GPT in 2 cases (4.4%), one of which also showed increased gamma-GTP.